{"nctId":"NCT02194088","briefTitle":"Combined Medication for Improved Analgesia in Superficial Pain","startDateStruct":{"date":"2014-04"},"conditions":["Pain"],"count":100,"armGroups":[{"label":"Pain medication: diclofenac and atropine","type":"EXPERIMENTAL","interventionNames":["Drug: Diclofenac and Atropine combination drug"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Diclofenac and Atropine combination drug","otherNames":["Analgesic drug","Combination drug","Test drug","Diclofenac and atropine","Atropine and diclofenac"]},{"name":"Placebo","otherNames":["Placebo control for the active medication"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female healthy volunteers.\n* 18-40 years of age.\n* Ability to read and understand English; English can be a second language provided that the participant feels that he/she understand all the questions used in the assessment measures.\n\nExclusion Criteria:\n\n* Chronic pain condition or chronic or current treatment with any pain medication.\n* Presence of any illness or medication use that is judged to interfere with the trial. For example: psychiatric disorder, medication that can influence cognition or emotional processing, i.e. sleep medication, antidepressants, anti-convulsants or opioids.\n* Unwillingness to receive brief pain stimulation administered by a heat probe on the hand.\n* Allergy or contra-indication to receiving nonsteroidal anti-inflammatory medication and atropine (Treatment with antidepressants, neuroleptics, antihistaminic, levodopa, anti-acids. Pregnancy, breast-feeding, myasthenia gravis, pyloric stenosis, gastro-esophageal reflux, gastric ulcer, constipation, prostatic enlargement, glaucoma, cardio-pulmonary condition -including tachycardia, arrhythmia, arteriosclerosis-, hyperthyroidism, high blood pressure, genetic disease, kidney failure)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Scores on Standardized Experimental Pain Testing","description":"Pain scores on standardized experimental pain testing, with collection of Visual analog scales (VAS) on a 0-100 scale 0 (no pain)- 100 (worst pain imaginable) Higher values represent a worse outcome (more pain)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":"13.9"},{"groupId":"OG001","value":"54.0","spread":"13.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":"22.7"},{"groupId":"OG001","value":"45.3","spread":"18.0"}]}]}]},{"type":"SECONDARY","title":"Catechol-O-methyltransferase (COMT) Polymorphism Correlation With Pain Relief","description":"Difference in the baseline pain measurements compared to the 1-hour outcome measure will be correlated with Catechol-O-methyltransferase polymorphism","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Side Effects","description":"The investigators aimed assess if these would be a reason for discontinuation of treatment in a population with mild to moderate pain.Side effects will be assessed with a dichotomous measurement (yes/no)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":[]}}}